Tennessee is currently home to 1922 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Nashville, Memphis, Knoxville and Chattanooga. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
DIAMOND AF Post-Approval Study
NCT05230524
Recruiting
The DIAMOND AF Post Approval study is a prospective, global, multi-center, non-randomized, single-arm observational trial
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: University of Tennessee Methodist Physicians, Memphis, Tennessee
Conditions: Paroxysmal Atrial Fibrillation
Register for Updates
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
NCT04870944
Recruiting
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Drugs, such as CBL0137, block signals passed from one molecule to another inside a cell. Blocking these signals can affect many functions of the cell, including cell division and cell death, and may kill cancer cells.
Gender:
ALL
Ages:
Between 12 months and 30 years
Trial Updated:
02/11/2025
Locations: Saint Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Malignant Neoplasm in the Central Nervous System, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Recurrent Primary Malignant Central Nervous System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Osteosarcoma, Refractory Primary Malignant Central Nervous System Neoplasm
Register for Updates
Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
NCT04713982
Recruiting
Examine the effects of deutetrabenazine on functional speech and gait impairment
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Huntington Disease
Register for Updates
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
NCT04363684
Recruiting
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Vanderbilt University, Nashville, Tennessee
Conditions: Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
Register for Updates
Generic Database of Very Low Birth Weight Infants
NCT00063063
Recruiting
The Generic Database (GDB) is a registry of very low birth weight infants born alive in NICHD Neonatal Research Network (NRN) centers. The GDB collects observational baseline data on both mothers and infants, and the therapies used and outcomes of the infants. The information collected is not specific to a disease or treatment (i.e., it is "generic"). Data are analyzed to find associations and trends between baseline information, treatments, and infant outcome, and to develop future NRN trials.
Gender:
ALL
Ages:
14 days and below
Trial Updated:
02/11/2025
Locations: University of Tennessee, Memphis, Tennessee
Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Register for Updates
Follow-up Visit of High Risk Infants
NCT00009633
Recruiting
The NICHD Neonatal Research Network's Follow-Up study is a multi-center cohort in which surviving extremely low birth-weight infants born in participating network centers receive neurodevelopmental, neurosensory and functional assessments at 22-26 months corrected age (Infants born prior to July 1, 2012 were seen at 18-22 months corrected age). Data regarding pregnancy and neonatal outcome are collected prospectively. The goal is to identify potential maternal and neonatal risk factors that may... Read More
Gender:
ALL
Ages:
Between 18 months and 26 months
Trial Updated:
02/11/2025
Locations: University of Tennessee, Memphis, Tennessee
Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Register for Updates
MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
NCT06171685
Recruiting
This trial is an adaptive platform trial. The structure of the protocol allows the trial to evolve over time. Multiple investigational arms will be included within the trial under a Master Protocol (MP). These investigational arms may be added as appendices at different times depending on whether they are trial-ready and whether accrual in the trial will support another arm. Accrual to an arm will terminate in accord with the arm's appendix to the Master Protocol. The purpose of this proposed s... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
02/10/2025
Locations: Tennessee Oncology, Nashville, Tennessee
Conditions: Relapse Multiple Myeloma, Refractory Multiple Myeloma
Register for Updates
Cardiovascular Magnetic Resonance Prognosticators in Pediatric Oncology Patients With Sepsis
NCT05930418
Recruiting
The overall purpose of this protocol is to identify subacute sepsis-associated cardiac disease in pediatric patients with cancer by CMR and evaluate the CMR findings during their follow-up. This will help inform heart failure management decision making. Evidence of dysfunction or elevated T2 values may inform adjustment of afterload reduction and beta blocker administration, and elevated ECV findings will suggest the need for increased surveillance for diastolic dysfunction. Primary Objectives:... Read More
Gender:
ALL
Ages:
Between 9 years and 25 years
Trial Updated:
02/10/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Acute Respiratory Distress Syndrome, Sepsis, Cardiovascular Shock
Register for Updates
An Evaluation of Concordance of Smartwatch ECG and One Clinical ECG and Comparison of The Two ECGS in Terms of Predictive Risks
NCT05617391
Recruiting
The participant is being asked to take part in this trial, because the participant is a survivor of childhood cancer. Primary Objective To evaluate remote cardiomyopathy prediction via smartwatch and one clinical ECG and assess the concordance of the two ECGs in terms of predicted risk. Secondary Objective To build a novel predictive model solely on smartwatch ECG to predict risk for cardiomyopathy.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
02/10/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Childhood Cancer, Cardiomyopathy, Primary
Register for Updates
Abatacept for the Treatment of Giant Cell Arteritis
NCT04474847
Recruiting
This randomized, double-blind, placebo-controlled trial will seek to determine the efficacy of abatacept in GCA. To examine this objective, 62 eligible patients who have newly diagnosed or relapsing GCA within 8 weeks prior to screening will be randomized at a 1:1 ratio to receive subcutaneous abatacept 125mg/week or placebo. Patients who achieve remission will remain on their blinded assignment for 12 months at which time abatacept/placebo will be stopped. Patients who do not achieve remission... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
02/10/2025
Locations: Vanderbilt University, Nashville, Tennessee
Conditions: Giant Cell Arteritis
Register for Updates
Vertebral Artery Origin Treatment Via Endovascular Techniques Registry (VOTER)
NCT03999983
Recruiting
A retrospective and prospective registry of patients admitted for stroke and evidence of Vertebral Artery Origin Stenosis (VAOS).
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
02/10/2025
Locations: Semmes Murphey Clinic, Memphis, Tennessee
Conditions: Vertebral Artery Stenosis
Register for Updates
Gastric Feeding Versus Transpyloric Feeding in Infants with Severe Bronchopulmonary Dysplasia, a Crossover Study
NCT06821776
Recruiting
Hospitalized infants with severe bronchopulmonary dysplasia (BPD) and feeding intolerance will be randomized to 2 weeks of continuous gastric feeding or continuous transpyoloric feeding. Subjects will crossover after 2 weeks and receive 4 weeks of each feeding mode. Respiratory status will be assessed to determine the optimal feeding mode for each infant.
Gender:
ALL
Ages:
Between 1 month and 1 year
Trial Updated:
02/06/2025
Locations: Le Bonheur Children's Hospital, Memphis, Tennessee
Conditions: Bronchopulmonary Dysplasia, Feeding Intolerance
Register for Updates